The new EU compulsory licensing regime needs to allow the export of medicines
Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London.
A war-weary Ukraine critically depends on the support of...
Modifier la législation européenne pour mettre en œuvre la licence d’office en France
Selon le Dr Thierry Philip, Président de l’institut Curie, la hausse des prix des nouveaux traitements contre le cancer « est devenue intenable. »
L’augmentation croissante du prix...
WHO is an essential forum for debates on intellectual property and public health
Recently, Health Policy Watch reported that some European countries at the World Health Organization (WHO) Pandemic Agreement negotiations maintain that intellectual property negotiations belong...
Wrapping up 2023 with some noteworthy medicines, law and policy developments
Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...
Brazil’s Federal Court Reviews Medicines Mailbox Patents
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...
Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade...
Negotiations are currently taking place at the World Health Organization (WHO) to conclude a new pandemic agreement by May 2024. The objective of the...
New Dutch Foundation to Address High Medicines Pricing Announces Plan to File Complaint with...
The newly established Dutch Pharmaceutical Accountability Foundation has announced its first action to address unreasonably high medicines prices in the Netherlands. The Foundation will...
EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
Wrapping up 2024: Noteworthy events in medicines law and policy around the globe
Welcome to Medicines Law & Policy’s end of the year blog, our highly biased annual overview of memorable medicines law and policy events.
January
At the...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...